Loomis, Sayles & Company
XENT

Loomis, Sayles & Company’s Intersect ENT, Inc XENT Stock Holding History

Loomis, Sayles & Company’s Portfolio XENT Stock Details XENT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-396
Closed -$13K – 782
2019
Q1 		$13K Hold
396
– – ﹤0.01% 707
2018
Q4 		$11K Hold
396
– – ﹤0.01% 780
2018
Q3 		$11K Sell
396
-542,204
-100% -$16.3M ﹤0.01% 800
2018
Q2 		$20.3M Buy
542,600
+347,408
+178% +$13.6M 0.04% 242
2018
Q1 		$7.67M Buy
195,192
+194,484
+27,469% +$7.1M 0.02% 478
2017
Q4 		$23K Buy
+708
New +$21.2K ﹤0.01% 750

Other funds holding XENT

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Loomis, Sayles & Company's XENT Position: Q2 2019 in Review

Loomis, Sayles & Company sold out of Intersect ENT, Inc (XENT) in Q2 2019, closing a stake of 396 shares — an estimated $13K sold.

Loomis, Sayles & Company first reported a position in XENT in Q4 2017 and held it in 6 quarters. The position peaked at $20.3M in Q2 2018. 112 funds tracked by Wall St. Rank hold XENT as of Q2 2019.

  • Loomis, Sayles & Company reported no remaining Intersect ENT, Inc position as of Q2 2019 after selling out during the quarter.
  • Loomis, Sayles & Company sold 396 Intersect ENT, Inc shares in Q2 2019, an estimated $13K.
  • Loomis, Sayles & Company first reported a position in Intersect ENT, Inc in Q4 2017 and held it in 6 quarters.
  • Loomis, Sayles & Company's Intersect ENT, Inc position peaked at $20.3M in Q2 2018.
  • 112 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2019.

Based on Loomis, Sayles & Company's 13F filing for Q2 2019, filed 14 Aug 2019.